Phase-3 trial for non-small-cell lung cancer fails

Monday 14 June 2010

Bayer Healthcare Pharmaceuticals and Onyx Pharmaceuticals Inc announced that a Phase 3 trial of Nexavar (sorafenib) failed to reach its primary endpoint of improving overall survival in study of some 900 patients with advanced non-squamous, non-small-cell lung cancer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States